AOD-9604 vs Semaglutide: GH Fragment vs GLP-1 Comparison
AOD-9604 is a modified fragment of human growth hormone (amino acids 177-191) designed to promote lipolysis without the growth or diabetogenic effects of full HGH. It failed Phase II obesity trials and has limited clinical evidence. Semaglutide is a GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, achieving 15-17% body weight loss in STEP trials with proven cardiovascular benefits. This comparison highlights the substantial evidence grade gap between a preclinical research peptide and a clinically validated therapeutic.
Side-by-Side Comparison
| Parameter | AOD-9604 | Semaglutide |
|---|---|---|
| Mechanism | GH fragment; beta-3 adrenergic lipolysis | GLP-1 receptor agonist; central appetite suppression |
| Evidence Grade | C+ | A+ |
| Clinical Trials | Failed Phase II for obesity | STEP 1-5, SUSTAIN, SELECT (all positive) |
| Weight Loss | Not significant vs placebo in trials | ~15-17% at 68 weeks (STEP-1) |
| Route | Subcutaneous injection | SC injection (weekly) or oral (daily) |
| Typical Dose | 250 - 500 mcg/day | 0.25 - 2.4 mg weekly |
| Half-Life | ~30 minutes | ~7 days |
| Best For | Lipolysis mechanism research | Proven weight loss, glycemic control, CV protection |
| FDA Status | Not FDA-approved; GRAS for food use only | FDA-approved (T2D + obesity) |
| Cost (research grade) | $ | $$$ |
AOD-9604: Pros & Cons
Advantages
- Very low cost
- No effect on blood glucose or IGF-1
- No growth-promoting effects
- Good safety profile in trials (well-tolerated)
- Interesting mechanism for lipolysis pathway research
Considerations
- Failed Phase II obesity clinical trials
- No significant weight loss vs placebo in humans
- Very short half-life (~30 minutes)
- Requires daily injection
- Limited evidence of clinical efficacy
- GRAS status only for food use, not therapeutic
Semaglutide: Pros & Cons
Advantages
- FDA-approved with the strongest evidence base
- 15-17% body weight loss demonstrated
- 20% MACE reduction (SELECT trial)
- Once-weekly dosing convenience
- Oral formulation available
- Strong glycemic control
Considerations
- Significantly higher cost
- GI side effects during titration
- Weight regain after discontinuation
- Muscle mass loss alongside fat loss
- Potential pancreatitis and gallbladder concerns
Which Is Right for Your Research?
Decision Guide
Choose AOD-9604 research if: You are studying the lipolytic fragment of growth hormone, beta-3 adrenergic pathway mechanisms, or need a low-cost research peptide for fat metabolism pathway studies. AOD-9604 has academic value for understanding GH-mediated lipolysis independent of growth effects, but should not be expected to produce meaningful weight loss based on clinical trial failures.
Choose semaglutide research if: You need clinically proven weight loss efficacy, cardiovascular outcome data, or the gold standard comparator for obesity therapeutics. Semaglutide is the most evidence-backed weight management compound available with FDA approval, STEP trial data, and SELECT cardiovascular outcomes. The evidence gap between semaglutide and AOD-9604 is one of the largest in peptide research.
Important note: AOD-9604 and semaglutide are not comparable in clinical evidence quality. Researchers should be aware that AOD-9604's popularity in the peptide community significantly exceeds its clinical evidence base.
Frequently Asked Questions
No. Semaglutide has Phase III data showing 15-17% weight loss. AOD-9604 failed Phase II trials with no significant weight loss over placebo. The evidence gap is substantial โ semaglutide is overwhelmingly better supported.
AOD-9604 is a simple 16-amino acid fragment, inexpensive to synthesize. Semaglutide is a complex acylated protein requiring sophisticated manufacturing, plus it has FDA approval and patent protection. The cost difference mirrors the evidence difference.
No. AOD-9604 is the lipolytic fragment of GH (aa 177-191) specifically designed to promote fat metabolism without diabetogenic or growth effects. It does not raise blood glucose, IGF-1, or promote tissue growth, though this selectivity did not translate to clinical weight loss efficacy.
Related Protocol Guides
Compare More
Verified Research Suppliers
- ★ LiveWell Peptides — Official Sponsor • cGMP Certified Paid partnership
- Core Peptides — Third-party tested
- Limitless Life Nootropics — Broad catalog
- Biotech Peptides — USA-based
- Amino Asylum — Budget-friendly
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.